Business Description
Theralase Technologies Inc
NAICS : 334512
SIC : 3912
ISIN : CA88337V1004
Total Employee Number:
14Description
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.33 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -0.13 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -7.76 | |||||
Beneish M-Score | -2.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.7 | |||||
3-Year EBITDA Growth Rate | 14.5 | |||||
3-Year EPS without NRI Growth Rate | 13.8 | |||||
3-Year FCF Growth Rate | 19.6 | |||||
3-Year Book Growth Rate | -20.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 463.72 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.24 | |||||
9-Day RSI | 42.68 | |||||
14-Day RSI | 44.13 | |||||
3-1 Month Momentum % | -16.84 | |||||
6-1 Month Momentum % | 55.52 | |||||
12-1 Month Momentum % | 27.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.37 | |||||
Quick Ratio | 1.11 | |||||
Cash Ratio | 0.54 | |||||
Days Inventory | 610.44 | |||||
Days Sales Outstanding | 23.88 | |||||
Days Payable | 1218.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7 | |||||
Shareholder Yield % | -5.61 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.96 | |||||
Operating Margin % | -432.83 | |||||
Net Margin % | -428.64 | |||||
EBITDA Margin % | -392.43 | |||||
FCF Margin % | -368.75 | |||||
OCF Margin % | -370.35 | |||||
ROE % | -256.16 | |||||
ROA % | -112.5 | |||||
ROIC % | -213.58 | |||||
3-Year ROIIC % | -26425 | |||||
ROC (Joel Greenblatt) % | -725.71 | |||||
ROCE % | -232.1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 58.21 | |||||
PB Ratio | 16.65 | |||||
Price-to-Tangible-Book | 16.65 | |||||
EV-to-EBIT | -18.16 | |||||
EV-to-EBITDA | -19.56 | |||||
EV-to-Revenue | 76.84 | |||||
EV-to-Forward-Revenue | 55.78 | |||||
EV-to-FCF | -20.84 | |||||
Price-to-GF-Value | 1.28 | |||||
Price-to-Median-PS-Value | 1.51 | |||||
Earnings Yield (Greenblatt) % | -5.51 | |||||
FCF Yield % | -4.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TLTFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theralase Technologies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.624 | ||
| EPS (TTM) ($) | -0.01 | ||
| Beta | 0.8922 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.35 | ||
| Volatility % | 73.65 | ||
| 14-Day RSI | 44.13 | ||
| 14-Day ATR ($) | 0.01391 | ||
| 20-Day SMA ($) | 0.168289 | ||
| 12-1 Month Momentum % | 27.13 | ||
| 52-Week Range ($) | 0.1019 - 0.3061 | ||
| Shares Outstanding (Mil) | 295.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theralase Technologies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theralase Technologies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Theralase Technologies Inc Frequently Asked Questions
What is Theralase Technologies Inc(TLTFF)'s stock price today?
The current price of TLTFF is $0.17. The 52 week high of TLTFF is $0.31 and 52 week low is $0.10.
When is next earnings date of Theralase Technologies Inc(TLTFF)?
The next earnings date of Theralase Technologies Inc(TLTFF) is .
Does Theralase Technologies Inc(TLTFF) pay dividends? If so, how much?
Theralase Technologies Inc(TLTFF) does not pay dividend.
Guru Commentaries on OTCPK:TLTFF
No articles.
Press Release
Articles on Theralase Technologies Inc
No articles.
Headlines
See More- 1
May 29, 2026
Theralase Technologies Inc. reports Q1 results
Seeking Alpha • 4:12pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers